Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 0.94 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.94 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.94 |
| ▸ | BLM | P54132 | 2/20 | 0.94 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.94 |
| ▸ | THRB | P10828 | 2/20 | 0.94 |
| ▸ | MEN1 | O00255 | 2/20 | 0.94 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.94 |
| ▸ | PLG | P00747 | 1/20 | 0.94 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.94 |
| ▸ | RECQL | P46063 | 1/20 | 0.94 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.94 |
| ▸ | TSHR | P16473 | 5/20 | 0.82 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.82 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.82 |
| ▸ | GABRP | O00591 | 1/20 | 0.82 |
| ▸ | GABRD | O14764 | 1/20 | 0.82 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adipic Acid SCHEMBL2537893 | 1.00 | NFKB1 (1.00) | NFKB1CYP2D6LMNAKMT2AALDH1A1 | |
| 5-Aminovaleric Acid SCHEMBL190150 | 1.00 | — | — | |
| SCHEMBL2778601 | 0.97 | LMNA (1.00) | NFKB1CYP2D6LMNAKMT2AALDH1A1 | |
| SCHEMBL4524913 | 0.97 | LMNA (1.00) | NFKB1CYP2D6LMNAKMT2AALDH1A1 | |
| SCHEMBL2231728 | 0.97 | LMNA (1.00) | NFKB1CYP2D6LMNAKMT2AALDH1A1 | |
| 5-Aminovaleric Acid SCHEMBL25349504 | 0.97 | — | — | |
| Pimelic Acid SCHEMBL21465298 | 0.97 | LMNA (1.00) | NFKB1CYP2D6LMNAKMT2AALDH1A1 | |
| 12-Aminododecanoic Acid SCHEMBL20767098 | 0.97 | LMNA (1.00) | NFKB1CYP2D6LMNAKMT2AALDH1A1 | |
| Aminocaproic Acid SCHEMBL21141584 | 0.97 | LMNA (1.00) | NFKB1CYP2D6LMNAKMT2AALDH1A1 | |
| Adipic Acid SCHEMBL10591067 | 0.97 | LMNA (1.00) | NFKB1CYP2D6LMNAKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113956348-A | Glucagon and GLP-1 co-agonist compounds | 伊莱利利公司 | 2022-01-21 | — | — | CN | claimed |
| EP-3785724-A1 | GLUCAGON AND GLP-1 CO-AGONIST COMPOUNDS | Eli Lilly and Company (US) | 2021-03-03 | — | — | EP | claimed |
| EP-3310371-A1 | GLUCAGON AND GLP-1 CO-AGONIST COMPOUNDS | Eli Lilly and Company (US) | 2018-04-25 | — | — | EP | claimed |
| US-9938335-B2 | Glucagon and GLP-1 co-agonist compounds | ELI LILLY AND COMPANY (US) | 2018-04-10 | — | — | US | claimed |
| CN-107735100-A | glucagon and G L P-1 synergistic agonist compounds | 伊莱利利公司 | 2018-02-23 | — | — | CN | claimed |
| WO-2016209707-A1 | GLUCAGON AND GLP-1 CO-AGONIST COMPOUNDS | ELI LILLY AND COMPANY (US) | 2016-12-29 | — | — | WO | claimed |
| US-20160368960-A1 | GLUCAGON AND GLP-1 CO-AGONIST COMPOUNDS | ELI LILLY AND COMPANY (US) | 2016-12-22 | — | — | US | claimed |
| US-11708564-B2 | Microorganism expressing active D-proline reductase and method of producing active D-proline reductase | CJ CHEILJEDANG CORPORATION (KR) | 2023-07-25 | — | — | US | disclosed |
| CN-113956348-A | Glucagon and GLP-1 co-agonist compounds | 伊莱利利公司 | 2022-01-21 | — | — | CN | disclosed |
| CN-107735100-B | Glucagon and GLP-1 co-agonist compounds | 伊莱利利公司 | 2021-11-05 | — | — | CN | disclosed |
| EP-3785724-A1 | GLUCAGON AND GLP-1 CO-AGONIST COMPOUNDS | Eli Lilly and Company (US) | 2021-03-03 | — | — | EP | disclosed |
| EP-3310371-B1 | GLUCAGON AND GLP-1 CO-AGONIST COMPOUNDS | LILLY CO ELI (US) | 2020-09-30 | — | — | EP | disclosed |
| US-20190214145-A1 | Method and systems for creating and screening patient metabolite profile to diagnose current medical condition, diagnose current treatment state and recommend new treatment regimen | KUREK ITZHAK (US) | 2019-07-11 | — | — | US | disclosed |
| US-8748130-B2 | Human papillomavirus / Ii-Key hybrids and methods of use | ANTIGEN EXPRESS, INC. (US) | 2014-06-10 | — | — | US | disclosed |
| EP-2376622-A2 | GREEN PROCESS AND COMPOSITIONS FOR PRODUCING POLY(5HV) AND 5 CARBON CHEMICALS | Metalbolix Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| EP-2344191-A1 | HUMAN PAPILLOMAVIRUS / LI-KEY HYBRIDS AND METHODS OF USE | Antigen Express, Inc. (US) | 2011-07-20 | — | — | EP | disclosed |
| US-20110039995-A1 | METHOD FOR IMPROVING THE STORAGE STABILITY OF AQUEOUS COMPOSITE PARTICLE DISPERSIONS | BASE SE (DE) | 2011-02-17 | — | — | US | disclosed |
| WO-2010068953-A2 | GREEN PROCESS AND COMPOSITIONS FOR PRODUCING POLY(5HV) AND 5 CARBON CHEMICALS | METABOLIX INC. (US) | 2010-06-17 | — | — | WO | disclosed |
| US-20100080817-A1 | HUMAN PAPILLOMAVIRUS / Ii-KEY HYBRIDS AND METHODS OF USE | NUGENEREX IMMUNO-ONCOLOGY, INC. | 2010-04-01 | — | — | US | disclosed |
| WO-2010027973-A1 | HUMAN PAPILLOMAVIRUS / LI-KEY HYBRIDS AND METHODS OF USE | ANTIGEN EXPRESS, INC. (US) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368960-A1 | GLUCAGON AND GLP-1 CO-AGONIST COMPOUNDS | GLP1R, GCGR, GIPR | NFKB1 4009/4885CYP2D6 1930/4885LMNA 3602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.